Not Just Another Index.
It’s The New Generation.®
We offer specialized solutions for investors seeking exposure to New Listings - a proxy for economic growth and innovation.
New: The IPOX® High Dividend 7% Strategy
An Innovative Index Strategy
combining Income & Growth!
Upcoming Global IPOs
The IPOX® Newsletters
IPOX® in the News
IPOX® Research Analyst Lukas Muehlbauer was featured in Reuters discussing Wealthfront’s $2.63 billion Nasdaq debut. While the fintech raised $484.6 million, its flat opening highlighted ongoing market caution. Muehlbauer noted that "investors are still selective," distinguishing between high-profile wins and mixed broader performance. His commentary underscores the critical nuance required when analyzing shifting sentiment within the recovering fintech IPO landscape.
In a recent Reuters article, IPOX® CEO Josef Schuster analyzes the successful $462.5 million IPO of Lumexa Imaging amidst the year-end market rush. Schuster highlights that while investor appetite exists for the "right deal," there is notable caution regarding sectors with poor post-IPO returns, such as Silicon Valley-backed crypto and AI ventures. Read more about his insights on the current selective IPO landscape.
Construction tech firm EquipmentShare revealed significant revenue growth in its recent US IPO paperwork. IPOX® Research Analyst Lukas Muehlbauer provided key insights on the filing, noting the company’s sensitivity to interest rates due to capital deployment for its rental fleet. Muehlbauer also discussed the broader market trend, suggesting companies are rushing filings to avoid potential volatility and uncertainty surrounding Federal Reserve leadership changes in 2026.
In a recent Reuters article, IPOX® CEO Josef Schuster analyzes Medline’s targeted $55 billion listing, poised to be 2025’s largest IPO. Dr. Schuster highlights the deal as a critical test for market breadth beyond tech, describing the company as an "amazing American growth story." His commentary underscores the vital role of public markets in funding expansion as Medline seeks to raise over $5 billion in this blockbuster offering.
IPOX® Analyst Lukas Muehlbauer comments on Andersen Group's $1.75 billion IPO in a recent Reuters article. Muehlbauer describes the listing as a "resurrection story" for the brand formerly linked to Arthur Andersen. He notes that the decision to list now suggests management is prioritizing immediate capital access over 2026 volatility, while strategically aligning the deal with strong financial results from tax-extension seasonality.
The IPOX® Update
SpaceX dominates headlines with plans for a record-breaking IPO targeting a $1.5 trillion valuation. IPOX® CEO Josef Schuster weighs in on the blockbuster pipeline, while IPOX® Associate Lukas Muehlbauer analyzes Wealthfront’s debut and EquipmentShare’s filing. Tax firm Andersen targets a $1.75 billion deal, Michael Burry eyes a Fannie Mae re-listing, and Magnum completes its spin-off, while Hong Kong sees crypto and robotics activity.
AI takes the lead as Anthropic preps for a potential 2026 IPO and Baidu’s Kunlunxin eyes a Hong Kong listing. IPOX® Associate Lukas Muehlbauer comments on Wealthfront’s $2.05 billion target amid mixed sentiment. Elsewhere, Unilever’s ice cream unit advances spin-off plans, Barrick Gold explores a North American IPO, and Morgan Stanley predicts a dealmaking surge, even as travel unicorn Klook delays its U.S. debut.
Bill Ackman targets a massive $5 billion IPO for a new closed-end fund, while sports tech firm Enhanced agrees to a $1.2 billion SPAC merger. IPOX® CEO Josef Schuster notes the SPAC model’s enduring relevance following the deal. Elsewhere, the UK introduces stamp duty relief to revitalize London listings, and Hong Kong sees a flurry of activity with Syngenta’s potential pivot and new filings from Suzhou Novosense and Muyuan Foods.